23 May 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell announces grant of European patent for its Moditope® immunotherapy platform
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, confirms that following its announcement on 9 February 2018, the European Patent Office will grant a European Patent for the Company's Moditope® immunotherapy platform with effect from 13 June 2018.
The patent will provide broad protection for the Company's pipeline of Moditope® vaccines, including any citrullinated epitopes for the treatment of cancer, in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey. Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.
Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented:
"This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins. We are now well positioned to develop a pipeline of new Moditope® therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma."
For Further Information:
Scancell Holdings Plc |
|
|
Dr John Chiplin, Chairman |
|
+44 (0) 20 3727 1000 |
Dr Cliff Holloway, CEO |
|
|
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker) |
|
|
Freddy Crossley/Emma Earl |
|
+44 (0) 20 7886 2500 |
|
|
|
FTI Consulting Mo Noonan/Simon Conway |
|
+44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website: www.scancell.co.uk
